
Trail cams catch chimpanzees sharing fruit — with alcohol. See ‘boozy' encounter
In what is believed to be a world first, trail cameras in western Africa have filmed and photographed wild chimpanzees sharing fruit containing alcohol.
But, was it intentional?
The first-of-its-kind discovery has raised more questions than answers for researchers working in Guinea-Bissau's Cantanhez National Park, according to a study published April 21 in the peer-reviewed journal Current Biology.
The team set up motion-activated trail cameras throughout the park to better study the feeding and sharing behaviors of wild chimpanzees. The chimpanzees in this park are 'unhabituated' to researchers, according to the study.
'Chimpanzees were seen to regularly select and feed on T. africana (African breadfruit) when available. Sharing was observed on 10 separate occasions between 17 individuals across all age- and sex-classes,' researchers said. 'At the time of sharing, 90% of the shared fruits contained ethanol.'
African breadfruit contains ethanol when fermented, so the researchers tested the fruit to see just how 'boozy' it really was, according to an April 21 news release from the University of Exeter.
When they calculated the fruit's alcohol by volume — the same measure used for alcoholic drinks — they found values up to 0.61% ABV, a 'relatively low' amount, according to the release.
A single serving of beer is 12 ounces, for example, and has an ABV of 5%, while a typical 5 ounces of wine has a 12% ABV. The ABV in the booziest African breadfruit was similar to that in kombucha, a fermented tea drink, which can have about 0.5% ABV.
'But the researchers say it may be the 'tip of the iceberg', as 60-80% of chimps' diet is fruit — so low levels of alcohol in various foods could add up to significant consumption,' according to the release.
The chimpanzees are, however, unlikely to get 'drunk' as it would be a significant hindrance to their survival chances, researchers said.
'Chimps don't share food all the time, so this behavior with fermented fruit might be important,' researcher Kimberley Hockings, from the University of Exeter, said in the release. 'We need to find out more about whether they deliberately seek out ethanolic fruits and how they metabolize it, but this behavior could be the early evolutionary stages of 'feasting.' If so, it suggests the human tradition of feasting may have its origins deep in our evolutionary history.'
The tradition of drinking and sharing alcohol runs deep in human history, with beer possibly being made as far back as 13,000 years ago, according to History.com.
'For humans, we know that drinking alcohol leads to a release of dopamine and endorphins, and resulting feelings of happiness and relaxation,' lead author Anna Bowland, from the Centre for Ecology and Conservation with the University of Exeter, said in the release. 'We also know that sharing alcohol — including through traditions such as feasting — helps to form and strengthen social bonds. So – now we know that wild chimpanzees are eating and sharing ethanolic fruits — the question is: could they be getting similar benefits?'
Cantanhez National Park is in southern Guinea-Bissau, a country on the west-central coast of Africa.
The research team includes Bowland, Hockings, Elena Bersacola, Marina Ramon, Joana Bessa, Amanda Melin, Matthew Carrigan and Xavier Harrison.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
New T-Rex ancestor discovered in drawers of Mongolian institute
Misidentified bones that languished in the drawers of a Mongolian institute for 50 years belong to a new species of tyrannosaur that rewrites the family history of the mighty T-Rex, scientists said Wednesday. This slender ancestor of the massive Tyrannosaurus Rex was around four metres (13 feet) long and weighed three quarters of a tonne, according to a new study in the journal Nature. "It would have been the size of a very large horse," study co-author Darla Zelenitsky of Canada's University of Calgary told AFP. The fossils were first dug up in southeastern Mongolia in the early 1970s but at the time were identified as belonging to a different tyrannosaur, Alectrosaurus. For half a century, the fossils sat in the drawers at the Institute of Paleontology of the Mongolian Academy of Sciences in the capital Ulaanbaatar. Then PhD student Jared Voris, who was on a trip to Mongolia, started looking through the drawers and noticed something was wrong, Zelenitsky said. It turned out the fossils were well-preserved, partial skeletons of two different individuals of a completely new species. "It is quite possible that discoveries like this are sitting in other museums that just have not been recognised," Zelenitsky added. - 'Messy' family history - They named the new species Khankhuuluu mongoliensis, which roughly means the dragon prince of Mongolia because it is smaller than the "king" T-Rex. Zelenitsky said the discovery "helped us clarify a lot about the family history of the tyrannosaur group because it was really messy previously". The T-Rex represented the end of the family line. It was the apex predator in North America until 66 million years ago, when an asteroid bigger than Mount Everest slammed into the Gulf of Mexico. Three quarters of life on Earth was wiped out, including all the dinosaurs that did not evolve into birds. Around 20 million years earlier, Khankhuuluu -- or another closely related family member -- is now believed to have migrated from Asia to North America using the land bridge that once connected Siberia and Alaska. This led to tyrannosaurs evolving across North America. Then one of these species is thought to have crossed back over to Asia, where two tyrannosaur subgroups emerged. One was much smaller, weighing under a tonne, and was nicknamed Pinocchio rex for its long snout. The other subgroup was huge and included behemoths like the Tarbosaurus, which was only a little smaller than the T-rex. One of the gigantic dinosaurs then left Asia again for North America, eventually giving rise to the T-Rex, which dominated for just two million years -- until the asteroid struck. dl/gil

Business Insider
2 days ago
- Business Insider
Elon Musk considers launching SpaceX rockets from South African soil
South African-born billionaire Elon Musk is reportedly exploring the possibility of launching SpaceX rockets and deploying Starlink low Earth orbit (LEO) satellites from his home country. Elon Musk is considering using the Denel Overberg rocket test site in South Africa for SpaceX launches and Starlink satellite deployments. The site is strategically suited for polar orbit launches, enhancing Starlink's ability to provide broadband to underserved regions. South Africa faces regulatory challenges that have delayed Starlink's operations despite potential benefits for the digital divide. The world's richest man, Elon Musk has expressed interest in using the Denel Overberg rocket test site near Arniston, outside Cape Town, for potential SpaceX launches. Developed by the Aerospace Systems Research Institute at the University of KwaZulu-Natal, the site has launched suborbital rockets up to 18km and is aiming for orbital capability by 2028. A SpaceX partnership could fast-track its readiness. According to The Daily Maverick, two space experts noted that the site's strategic value lies in its ideal position for launching satellites into polar orbits—particularly those passing over the South Pole—as well as for deploying Starlink's LEO satellites to deliver broadband internet to consumers, especially in underserved areas. The tech mogul, who is currently in a public feud with the U.S. President Donald Trump, appears to be turning his gaze back to South Africa as a prospective site for future space operations. While specific details remain under wraps, sources close to the matter suggest Musk is seriously evaluating South Africa 's strategic potential for both SpaceX and Starlink expansion. This move could mark a historic milestone, positioning the African continent as a new player in global space infrastructure. Starlink's turbulent run in South Africa Starlink, Elon Musk's satellite internet venture, has already launched operations across several African countries, delivering high-speed internet to underserved and remote regions. However, in South Africa, Musk's country of birth, the rollout has hit significant roadblocks despite early optimism about its potential to help bridge the nation's digital divide. Regulatory delays, licensing challenges, and questions surrounding local compliance have stalled Starlink's entry into the South African market. Tensions escalated further following President Cyril Ramaphosa's recent appearance in Washington and Musk's public criticism of the South African government for failing to approve Starlink's operations. In response, the South African government has initiated a review of its Broad-Based Black Economic Empowerment (B-BBEE) policy, particularly as it relates to foreign tech companies like Starlink. Launching satellites directly from South Africa would not only accelerate Starlink's service across the continent but could also support Musk's broader ambition of expanding access to internet connectivity globally.


Business Insider
3 days ago
- Business Insider
CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's...
Results in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) ('CERo' or the 'Company') an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by the European Patent Office, all of which significantly expand the Company's intellectual property portfolio. The USPTO granted U.S. Patent No. 12,291,557, titled, 'CHIMERIC TIM4 RECEPTORS AND USES THEREOF' on May 6, 2025. The granted claims cover certain design aspects of CER-1236, the Company's lead compound. This patent provides composition of matter protection for a chimeric TIM4 receptor comprising a TIM4 binding domain and canonical T cell signaling domains. Additionally, the European Patent Office has allowed European Patent Application No. 1882166.7 titled, 'CHIMERIC ENGULFMENT RECEPTOR MOLECULES AND METHODS OF USE' on May 16, 2025. The allowed claims encompass a chimeric engulfment receptor comprising a TIM4 binding domain and TLR2 signaling domain. The allowance of this European patent application expands protection of additional design aspects of CER-1236, which have already been granted in the U.S., Japan, and China. Finally, the USPTO granted U.S. Patent No. 12,303,551, titled, 'CELLULAR IMMUNOTHERAPY COMPOSITIONS AND USES THEREOF,' on May 20, 2025. This patent provides coverage for combination cellular immunotherapy compositions and methods of use for CER-1236. The patent covers combination of a chimeric engulfment receptor CD4 + T cell (CD4 + CER-T cell) with a chimeric antigen receptor CD8 + T cell (CD8 + CAR-T cell) or T cell receptor CD8 + T cell (CD8 + TCR-T cell), and their use to treat cancer. This type of combination therapy could be an exciting avenue to complement the CER-T cell technology with other powerful anti-cancer therapies. CERo's intellectual property portfolio now includes 9 total patent families with protection out to 2042 in the United States. With these additional granted patents and allowed application, CER-1236 and its platform technology is supported by 18 total issued patents and allowed patent application internationally. Chris Ehrlich, CERo Therapeutics CEO, commented, 'We continue to aggressively expand our intellectual property portfolio, as it ensures CERo's success in the market. These patents protect the core innovations of the CER-T technology that differentiate it from other cell therapies and demonstrate the true novelty of our design . We continue to seek a robust range of patents across multiple geographies that cover this technology in general, and CER-1236 in particular. The appreciation of the novelty of the CER-T technology by the patent offices validates the innovation and therapeutic potential of this approach, and we believe that we will continue to grow the portfolio. In the near term, we anticipate updates on our clinical trial progress in AML, and the announcement of initiating human trials to treat ovarian and non-small cell lung cancers.' About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ('CER-T'). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ('CAR-T') cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo has commenced clinical trials for its lead product candidate CER-1236 for hematological malignancies. This communication contains statements that are forward-looking and as such are not historical facts. This includes, without limitation, statements regarding the financial position, business strategy and the plans and objectives of management for future operations of CERo. These statements constitute projections, forecasts and forward-looking statements, and are not guarantees of performance. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this communication, words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predict,' 'project,' 'should,' 'strive,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo's management. Actual results could differ from those implied by the forward-looking statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and the documents incorporated by reference therein. The risks described in CERo's filings with the Securities and Exchange Commission are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.